Abstract
Activities performed in clinical monitoring and data management should ultimately lead to a final clinical database that is complete, accurate, free from implausible data, and substantiated by the source data at investigator sites and on case report forms (CRFs). This constitutes the basis for statistical analysis, which ultimately leads to the final study report.
Typically, clinical trials are described in a chronological manner: monitoring, data management, then statistics. Procedures for all clinical trial processes can be optimized, however, if not only trial statisticians but also clinical research associates (CRAs) responsible for monitoring the sites and data managers have a clear understanding of the critical variables of the study and the requirements of the clinical study report, right from the start. Applying an inverted perspective on the sequence of clinical processes leads to interesting insights and offers improvement potential.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH—Efficacy Topic 3: Structure and Contents of Clinical Study Reports, Step 4. November 30, 1995. Available at www.ich.org/LOB/media/MEDIA479.pdf
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH—Efficacy Topic 9: Statistical Principles for Clinical Trials. Step 4. February 5, 1998. Available at www.ich.org/LOB/media/MEDlA485.pdf
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH—Efficacy Topic 6: Guideline for Good Clinical Practice, Step 5, May 1, 1996 (CPMP/1CH/135/95). Available at www.ich.org/LOB/media/MEDIA482.pdf
Society for Clinical Data Management. Good Clinical Data Management Practices, 4th ed., October 2005. Available at: www.scdm.org.
Shen LZ, Zhou J. A practical and efficient approach to database quality audit in clinical trials. Drug Inf J. 2006:40:385–393.
Hattemer-Apostel R. Reinhardt W. Audits in data management, statistics and medical writing: auditing clinical databases, trial reports and related systems. In: GCP Auditing-Methods and Experiences. 2nd ed. Aulendorf: ECV Editio Cantor Verlag; 2007:188–205.
Institute of Medicine. Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making—Workshop Report. Washington. DC: National Academies Press; 1999.
Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use. as well as the requirements for authorisation of the manufacturing or importation of such products. OJ L 91/13–91/19, April 9, 2005.
US Food and Drug Administration. Compliance Program Guidance Manual 7348.810—Sponsors. Contract Research Organizations and Monitors, February 21, 2001. Available at www.fda.gov/ora/compliance_ref/bimo/7348_810/48–810.pdf
US Food and Drug Administration. Guidance for Industry: Computerized Systems Used in Clinical Trials, April 1999. Revised version published in May 2007: FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations. Available at www.fda.gov/OHRMS/DOCKETS/98fr/04d-0440-gdl0002.pdf
Hattemer-Apostel R. QM toolbox: Pareto’s 80:20 rule. SPAQA Circle. 2004;(15):6–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hattemer-Apostel, R., Fischer, S. & Nowak, H. Getting Better Clinical Trial Data: An Inverted Viewpoint. Ther Innov Regul Sci 42, 123–130 (2008). https://doi.org/10.1177/009286150804200204
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150804200204